Clinical trial NCT07004868: Inflammation, Cachexia and Therapeutic Response in Lung Cancer Treated With Immune Checkpoint Inhibitors: Exploratory Observational Study
Official title: Inflammation, Cachexia and Therapeutic Response in Lung Cancer Treated With Immune Checkpoint Inhibitors: Exploratory Observational Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Lung Cancer (NSCLC)
Keywords: immune checkpoint inhibitors
inflammation
cachexia
Lead sponsor: University Hospital, Tours
Sponsor class: OTHER
First posted: 2025-06-04
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients with a lung cancer treated with immune checkpoint inhibitors

Brief summary: Lung cancer is the leading cause of cancer-related death in France and globally, with 2.48 million new cases diagnosed in 2022, accounting for nearly 13% of global cancer incidence. Despite recent advances, it remains a major health issue due to late-stage diagnosis and high patient and societal burden. New insights into tumor and immune pathways have led to the development of targeted therapies, including tyrosine kinase inhibitors and therapeutic antibodies. Among these, immune checkpoint inhibitors (ICIs) such as nivolumab, pembrolizumab, atezolizumab, and durvalumab have significantly improved outcomes for some patients by reactivating T-cell responses.

The LCAb (Lung Cancer Antibodies) research project focuses on studying the interindividual variability of clinical response to ICI in lung cancer. These therapies are now used across various lung cancer types and stages, including early and advanced disease. Most ICIs are administered at fixed doses, without considering patient-specific factors as blood concentrations, tumor burden, body weight or nutritional status. The study hypothesizes that fixed dosing may affect treatment response and survival outcomes, highlighting the need for more personalized approaches.

Detailed description: Lung cancer is the leading cause of cancer-related death in France and worldwide. Its incidence is significant, with 2.48 million new cases diagnosed in 2022, representing nearly 13% of the total global cancer incidence. Despite recent therapeutic advances, it remains a major public health issue due to its frequent diagnosis at a metastatic stage, which results in high morbidity and mortality for patients and significant costs for society.

A better understanding of tumor and immune signaling pathways has recently led to the discovery of new molecular targets, such as immune checkpoints. The therapeutic arsenal against lung cancer has thus expanded to include new molecules such as tyrosine kinase inhibitors and therapeutic antibodies (Abs). The latter represent the majority of anticancer biotherapies, with more than 50 approved agents for solid or hematologic cancers.

In particular, antibodies targeting immune checkpoints (ICIs - immune checkpoint inhibitors), such as nivolumab, pembrolizumab, atezolizumab, and durvalumab, have revolutionized the management of certain lung cancer patients by reversing T-cell exhaustion, allowing some of them to become long-term responders.

The research project "Pharmacokinetics of Immune Checkpoint Inhibitor Antibodies Used in Lung Cancer" (LCAb - Lung Cancer Antibodies) aims to study the blood concentrations and pharmacokinetics of various ICI-type antibodies used in the treatment of lung cancer.

Lung cancer is characterized by multiple histological types, stages, and molecular profiles, each associated with different therapeutic options. ICI-type antibodies have numerous indications in lung cancer, and these indications have continued to expand in recent years. They are now used not only in metastatic stages but also in localized and locally advanced stages. These molecules have led to a marked improvement in the prognosis of lung cancer patients. However, their effectiveness varies from one patient to another.

The study focuses on anti-PD-1 and anti-PD-L1 ICI antibodies used routinely in lung cancer, regardless of histology or stage, whether administered alone or in combination with chemotherapy. Most of these antibodies are administered at a fixed dose, without adjustment for age, weight, general health, or nutritional status of the patients.We hypothesize that the use of fixed-dose ICIs in lung cancer may influence therapeutic response and patient survival.

Eligibility criteria: Inclusion Criteria:

* Age greater than or equal to 18 years
* Diagnosis of lung cancer, any histology, any stage
* Treatment with Ab ICI, with or without chemotherapy
* 1st administration of Ab ICI

Exclusion Criteria:

* Patient not followed at the CHRU de Tours
* Person under protective supervision
* Opposition to data processing

Primary outcomes:
measure: time to progression
timeFrame: Month 36
Secondary outcomes:
measure: weight
timeFrame: from day 0 to month 36 at each patient visit
measure: Serum CRP concentration
timeFrame: from day 0 to month 36 at each patient visit
measure: Serum Ab ICI concentration
timeFrame: from day 0 to month 36 at each patient visit
measure: Drug toxicity
timeFrame: from day 0 to month 36 at each patient visit
measure: Overall survival
timeFrame: from day 0 to month 36 at each patient visit
Other outcomes:
Locations:
city: Tours
country: France
facility: university hospital, Tours
Study officials:
affiliation: University Hospital, Tours
name: Marion FERREIRA, Dr
role: PRINCIPAL_INVESTIGATOR
References: